Barrington Research Downgrades Hologic (HOLX) to Market Perform
Barrington Research downgraded Hologic (NASDAQ: HOLX) from Outperform to Market Perform.
Analyst Charley R. Jones said, "We are downgrading HOLX to a MARKET PERFORM rating from an OUTPERFORM rating as we would prefer to wait for a better risk/reward. We certainly recognize that the transformation to 3-D is just beginning. We are finally going to get some service growth in the breast health division, which has struggled during the transition to 3-D as a result of the one-year lag on service due to the first year being free as part of a manufacturer warranty. We are also aware that NovaSure has already gone through a meaningful step down in revenue, but the fact is that there are headwinds in each of HOLX’s other segments and at nearly 20x and a 40% debt to cap, we’d rather wait."
Shares of Hologic closed at $25.86 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham & Company Downgrades Zimmer Holdings (ZMH) to Buy
- Mednax (MD) PT Raised to $80 at Jefferies
- Cowen Trims PT on Google (GOOGL) to $640; FX, 1x Items Hit Q4 Results, Core Ops Solid (GOOG)
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!